The Power of Giving Back
GivingTuesday – the global day of giving Join us for the 7th annual GivingTuesday on December 3, 2019! GivingTuesday is a global day of giving that happens each year after Black Friday and Cyber Monday. It’s a time when Canadians, charities and businesses come together to celebrate giving and participate in activities that support charities and non-profits. There […]
A DMD gene therapy has been placed on clinical hold
Following the occurrence of a safety incident, the FDA has placed on hold the clinical trial for SGT-001, the Solid’s gene therapy candidate for Duchenne muscular dystrophy (DMD). This clinical hold is the second bad news the DMD community has received this month. Last week, Swiss pharma giant Roche announced it was terminating its study of […]
Teaming up to take down Duchenne
Research and collaboration are bringing Canadians closer to a cure than ever before. However, many parents fear that access to treatment may come too late for their child. by Denise Deveau, Sep 6, 2019, > published on Maclean’s A community-based initiative led by Jesse’s Journey, in collaboration with Stand for Duchenne Canada. For […]
CARL’S RESILIENCE
Notes from the “Living with DMD” web-doc Tecima Productions team. Our small production team travelled across Canada, meeting with families whose children have Duchenne Muscular Dystrophy (DMD). We met with Dakota (age 6), Anakin (age 11) and Carl (age 35) at critical moments in their journey. Our goal was to produce a Web-doc in three […]
A Race Against Time to Access New Treatments
Duchenne muscular dystrophy seen through the eyes of the families There are over 7,000 rare diseases in Canada. Duchenne muscular dystrophy (DMD) is one of them. DMD afflicts children, especially young boys, and sometimes girls. This degenerative muscle disease causes loss of the ability to walk, heart and respiratory failure, and usually leads to premature […]
Correcting nonsense mutations with CRISPR/cas9?
Correcting nonsense mutations with CRISPR / Cas9? Would it be possible to correct nonsense mutations with CRISPR/Cas9? Some patients with DMD have a point mutation (nonsense) that leads either to the absence or to the abnormal function of dystrophin. The objective of Professor Jacques P. Tremblay’s team is to develop therapies for DMD due to […]
